Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care - OncLive
CheckMate 9ER trial data shows cabozantinib plus nivolumab improves PFS, OS, and ORR in RCC, similar to other TKI/immunotherapy combinations, though favorable-risk patients see less benefit. Combination regimens are more tolerable than sunitinib, with potential post-discontinuation benefits.
Related Clinical Trials
Reference News
Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care - OncLive
CheckMate 9ER trial data shows cabozantinib plus nivolumab improves PFS, OS, and ORR in RCC, similar to other TKI/immunotherapy combinations, though favorable-risk patients see less benefit. Combination regimens are more tolerable than sunitinib, with potential post-discontinuation benefits.